Eli Lilly with promising oncology presentations at ESMO
September 29, 2019 Off

Eli Lilly with promising oncology presentations at ESMO

By Dino Mustafić

Eli Lilly on Sunday presented data from results of testing its two oncology products; for registration of oral selpercatinib monotherapy, for the treatment of RET-altered thyroid cancers, and its abemaciclib branded Verzenio in combination with fulvestrant significantly extended life by a median of 9.4 months in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer

September 29, 2019 Off

Merck’s Keytruda showed increase in pathological complete response with chemotherapy versus neoadjuvant therapy chemotherapy in early-stage triple-negative breast cancer

By BusinessWire

Merck’s trial of Keytruda plus chemotherapy, followed by adjuvant Keytruda as monotherapy, which was granted Breakthrough Therapy designation (BTD) by the U.S. Food and Drug Administration (FDA) for the neoadjuvant treatment of patients with high-risk, early-stage TNBC plus chemotherapy, resulted in a statistically significant increase in pathological complete response (pCR) versus chemotherapy.

Five-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma
September 28, 2019 Off

Five-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma

By BusinessWire

Bristol-Myers squib’s Opdivo combined with Yervoy resulted in 52% of patients with being alive at five years, while 74% of patients treated with Opdivo plus Yervoy who were alive at five years remained treatment-free, the longest follow-up to date results for dual Immuno-Oncology (I-O) therapy in a Phase 3, randomized, controlled trial showed.